The NIH's Accelerating Medicines Partnership could be used as a model for efforts that will increase compound survival rates in early-stage studies, John LaMattina writes. He envisions an initiative involving the same organizations discussing and learning from their experience with Phase I compound attrition, which could be used to develop best practices that all biopharmaceutical companies could benefit from, he writes.

Full Story:

Related Summaries